This procedure is recommended for the extraction of a variety of diuretics from urine using non-polar polymeric SPE. The analyte suite includes thiazides, carbonic anhydrase inhibitors, loop and potassium sparring diuretics, with wide ranging pKa and logP values.
Amiloride, Acetazolamide, Hydrochlorothiazide, Methazolamide, Hydroflumethiazide, Furosemide, Bendoflumethiazide, Bumetanide, Spironolactone, Ethacrynic acid.
EVOLUTE® EXPRESS ABN 100 mg/3 mL (Tables), part number 610-0010-BXG.
Spike urine sample with at 50 ng/L concentration of the compounds listed above.
Dilute urine sample (1–2 mL) with 1% formic acid (1:1, v/v).
Methanol (3 mL).
0.1% (v/v) formic acid (3 mL).
Apply diluted sample.
Rinse with water/methanol (95:5, v/v, 3 mL).
Methanol (3 mL).
Evaporate to dryness and reconstitute in water/methanol (50:50, v/v, 1 mL) for subsequent LC-MS/MS analysis.
Waters 2795 Liquid Handling System (Waters Assoc., Milford, MA, USA).
Zorbax Eclipse XDB C18 3.5 μm analytical column(100 x 2.1 mm ID) (Agilent Technologies, Berkshire, UK).
C8 guard column (Agilent Technologies, Berkshire, UK).
0.1% aqueous formic acid and MeCN at a flow rate of 0.25 mL/min.
0.1% aqueous formic acid and 10% (v/v) MeCN at a flow rate of 0.25 mL/min increasing to 90% (v/v) MeCN over 7 minutes. The high concentration organic mobile phase was held for 1 minute then returned to the initial starting conditions.
10 μL.
Ambient temperature
Ultima Pt triple quadrupole mass spectrometer (Waters Assoc., Manchester, UK) equipped with an electrospray interface for mass analysis. Positive ions were acquired in the multiple reaction monitoring mode (MRM).
350 °C
100 °C
2.9 x 10-3mbar
The base peak in each compound spectrum was attributed to the protonated, [M+H]+ or deprotonated molecular ions [M-H]-and were subsequently used as the precursor ions in the resulting MRM transitions. Positive/negative ion switching was utilized to analyse all the diuretics in this suite. Full MRM transitions and ionization conditions are shown in Table 1.
Note: This work was originally performed using EVOLUTE® ABN 100 mg/10 mL cartridges.
|
Scan Function |
Analyte |
MRM Transition |
Ionization Polarity |
Cone Voltage (V) |
Collision energy (eV) |
|
1 |
Amiloride |
223.1 > 181.1 |
+ |
35 |
12 |
|
|
Acetazolamide |
230.1 > 189.1 |
+ |
35 |
15 |
|
2 |
Hydrochlorothiazide |
296.1 > 269.0 |
- |
100 |
19 |
|
3 |
Methazolamide |
237.1 > 195.1 |
+ |
35 |
12 |
|
4 |
Hydroflumethiazide |
330.1 > 303.0 |
- |
100 |
19 |
|
5 |
Furosemide |
329.1 > 285.0 |
- |
35 |
15 |
|
6 |
Bendoflumethiazide |
420.1 > 289.1 |
- |
100 |
22 |
|
7 |
Bumetanide |
365.2 > 240.2 |
+ |
35 |
15 |
|
8 |
Spironolactone |
417.2 > 341.2 |
+ |
35 |
14 |
|
9 |
Ethacrynic acid |
301.1 > 243.1 |
- |
35 |
12 |
|
Analyte |
% Recovery |
% RSD |
|
Amiloride |
100 |
1 |
|
Acetazolamide |
94 |
6 |
|
Hydrochlorothiazide |
104 |
1 |
|
Methazolamide |
94 |
5 |
|
Hydroflumethiazide |
100 |
2 |
|
Furosemide |
102 |
5 |
|
Bendoflumethiazide |
94 |
7 |
|
Bumetanide |
87 |
7 |
|
Spironolactone |
80 |
10 |
|
Ethacrynic acid |
91 |
8 |
|
Part Number |
Description |
Quantity |
|
610-0010-BXG
|
EVOLUTE® EXPRESS ABN 100 mg/ 3 mL (Tables) Cartridges |
50 |
Literature Number: AN700